Status:
TERMINATED
The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Society of Critical Care Medicine
Conditions:
Critically Ill
Hypoglycemia
Eligibility:
All Genders
21-75 years
Phase:
PHASE2
Brief Summary
The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.
Detailed Description
All patients whom on admission to the ICU (surgical, burn, \& cardiac) who are expected to receive intensive insulin therapy for at least 72 hours are eligible to be enrolled. Once enrolled, the patie...
Eligibility Criteria
Inclusion
- Men and women age \> 21 to 75 years of age.
- All subjects who meet ICU specific criteria for inclusion in their glucose protocol and placed on insulin infusion protocol as standard of care.
- Able to obtain patient or proxy consent.
Exclusion
- Current diagnosis of malignancy.
- Type 1 diabetes.
- Inability to obtain informed consent.
- On any Phase 1 trial.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00798590
Start Date
December 1 2008
End Date
June 1 2011
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224